Johns Hopkins University
The investigators aim to determine the effects of a novel drug on brain function and brain chemistry in patients with schizophrenia.
Many symptomatic domains in schizophrenia, with the exception of positive symptoms, are inadequately addressed by currently available antipsychotics, all of which rely on dopamine D2 receptor blockade. This blockade also elicits several major side effects. Conversely, some atypical antipsychotics possess additional receptor-binding capacities (e.g., targeting 5-HT2A and 5-HT7 receptors) and exhibit some efficacy against non-positive symptoms, such as cognitive dysfunction. Focusing on these clinico-pharmacological features, DSP has developed a novel compound that selectively binds to 5-HT2A an…
Inclusion Criteria: * right-handed, participants with schizophrenia between the ages of 18-50 years. Exclusion Criteria: * Current substance misuse * Pregnancy or breast feeding * Subjects with electrocardiographic abnormalities (particularly QTc prolongation) * Subjects with renal impairment * Subjects with hepatic impairment * Past or current neurological disorder (including stroke, brain tumor, epilepsy, Alzheimer's, Parkinson's or Huntington's disease) * Non-schizophrenia cause of cognitive impairment * Uncontrolled medical disorder that may interfere with cognition or compromise safety…
a single oral dose of DSP-2342 on brain chemistry and brain activity in adults with schizophrenia.
Arctuva estimate
Verify or correct the compensation shown for this listing.